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ORIGINAL ARTICLE
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ABSTRACT
Purpose: Clinical trials have demonstrated efficacy of vedolizumab in ulcerative colitis (UC) and
Crohn’s disease (CD). Further real-world data is needed to inform clinical practice. The primary out-
come was to assess corticosteroid-free and clinical remission after vedolizumab initiation. Secondary
outcomes included effect on disease activity scores, biochemical markers, concomitant drug use, endo-
scopic remission, surgical intervention, hospital admissions and adverse events.
Materials and methods: A multi-centre retrospective observational study was conducted with
patients initiated on vedolizumab across seven UK hospitals 1/11/14-30/11/16. Clinical disease activity
was assessed using the partial Mayo Scores (pMS) and Harvey Bradshaw Index (HBI). Clinical remission
was defined as HBI 4 or pMS <2 with a combined stool frequency and rectal bleeding sub score of
1. Clinical response was defined as 2-point decrease from baseline in pMS and 3-point decrease
from baseline in HBI.
Results: One hundred ninety-two patients were included in the final analysis. 45% of UC and 10% of
CD patients were anti-TNF naive. Over the observation period corticosteroid-free remission rates for
UC and CD were 46% and 45%, while clinical remission rates were 52% and 44%, respectively. Time to
corticosteroid free remission for UC and CD was 17.6 [IQR: 8.7–29.6] and 14.1 [QR: 6.0–21.7] weeks,
respectively. Time to clinical response for UC was 9.4 [IQR: 5.7–15.4] and CD was 9.5 [IQR: 6.1–18.2]
weeks. There was a substantial decrease in the concomitant use of immunomodulators and a similar
decrease in concomitant corticosteroid use over the study period.
Conclusions: Results in this predominately anti-TNF experienced population mirror other published
real-world data, demonstrating good clinical effectiveness and a comparable safety profile.
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Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic
relapsing inflammatory diseases of the colon and gastrointes-
tinal tract (GI). The estimated prevalence for UC is 250 per
100,000 and 150 per 100,000 for CD [1]. Due to the age of
onset and disease duration, IBD medical management incurs
a significant financial impact on world-wide healthcare sys-
tems [2]. The introduction of anti-tumour necrosis factor
(anti-TNF) therapies with an established efficacy has greatly
improved options for IBD patients, leading to an improve-
ment in quality of life, reduction in hospitalisation and surgi-
cal procedures [3–7]. However, despite the advances in
biologic therapy, the rates of primary non-response still
remain significant at approximately 30%, and 23%–46% of
patients lose response over time, during the maintenance
treatment [8–10]. New agents with alternative mechanisms
of action have been developed.
Vedolizumab is a humanised monoclonal antibody that
binds specifically to the a4b7 integrin, a mediator of gastro-
intestinal inflammation [11,12]. Binding to a4b7 on memory
T-helper lymphocytes inhibits the adhesion to mucosal
addressin cell adhesion molecule-1 (MAdCAM-1) expressed
on gut endothelial cells. The inhibition of this interaction
prevents the transmigration of gut-homing memory T cells
across the vascular endothelium and the subsequent
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inflammation [13,14]. The pivotal large-scale GEMINI clinical
trials have demonstrated safety and efficacy of vedolizumab
in both CD and UC with clinical remission rates of 39% and
42% maintained at 12months [15,16]. Vedolizumab is effect-
ive in the treatment of anti-TNF naive and anti-TNF failure
patients and benefits may continue long-term regardless of
exposure status [17–19]. However, anti-TNF naive CD
patients tend to respond better than those with previous
exposure [18,20]. Vedolizumab was granted a Food and
Drug Administration (FDA) and European Medicine Agency
(EMA) licence for the treatment of moderate to severe UC
and CD in 2014. Although clinical trial data is the gold
standard on which to base recommendations, results
obtained are not always generalisable in clinical practice.
Clinical trial patient selection, efficacy outcomes, generaliz-
ability and reproducibility vary in comparison to clinical
practice. Clinical trials also often lack data that is useful to
clinicians and patients, such as time to first clinical remis-
sion and response and adverse events in real-world clinical
practice. Robust data is required in the real-world setting to
help inform practice and the appropriate place of vedolizu-
mab in the IBD treatment algorithm. The recent LOVE-CD
study aims to evaluate the efficacy of early versus late use
of vedolizumab in CD [21]. While there are phase 3b stud-
ies demonstrating the efficacy of vedolizumab (for example,
the VERSIFY study [22]), a limited number of real-world
studies on vedolizumab have been published to date with
only a few based in the UK [23–25].
We report the first real-world experience of vedolizumab
in the treatment of IBD in the East Midlands. The primary
objective was to describe rates of corticosteroid-free remis-
sion and clinical remission in patients with IBD after initiation
on vedolizumab over the observation period. Secondary
objectives were to describe the change in disease activity
scores, median time to remission and response, concomitant
drug use, endoscopic remission, surgical treatment, IBD-
related hospital admissions and adverse events after initi-
ation on vedolizumab.
Materials and methods
Study population and design
A multicentre retrospective observational study was con-
ducted with all patients initiated on vedolizumab across
seven UK hospitals in the East Midlands. The participating
centres included both large tertiary sites and smaller district
general hospitals (Nottingham University Hospitals NHS
Trust, University Hospitals of Derby and Burton NHS
Foundation Trust, Sherwood Forest Hospitals NHS
Foundation Trust, University Hospitals of Leicester NHS Trust,
Chesterfield Royal Hospital NHS Foundation Trust, United
Lincolnshire Hospitals NHS Trust and Kettering General
Hospital NHS Foundation Trust). The study was designed and
conducted according to the requirements of the European
Network of Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP) [26] and International Society
for Pharmacoepidemiology (ISPE) guidance [27]. The study
protocol was approved by the Health Research Authority
(19/HRA/0008). This study was conducted as part of a
regional service improvement project, therefore, NHS REC
approval or written informed consent was not required. NHS
approval for local conduct of the study and the sharing of
anonymised patient data was sought and granted from the
Research and Development (R&D) department in each centre.
Patients initiated on vedolizumab between 1st November
2014 and 30th November 2016 were followed up until 31st
March 2017 (Figure 1).
Vedolizumab was prescribed as recommended by the
manufacturer, induction consisted of intravenous vedoli-
zumab 300mg at weeks 0, 2 and 6. Maintenance con-
sisted of intravenous vedolizumab 300mg every 8 weeks
until treatment discontinuation or the last follow-up. The
dosages of concomitant 5-ASAs, corticosteroids (prednis-
olone, hydrocortisone, budesonide, beclomethasone) and
immunomodulators (azathioprine, mercaptopurine, cyclo-
sporin, methotrexate) were recorded at each clin-
ical visit.
Figure 1. Observation period.
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Inclusion and exclusion criteria
Patients aged 18 years or older at initiation of vedolizumab,
with a diagnosis of CD, UC or IBD of unclassified type (IBD-U)
confirmed by endoscopic, radiological and histological crite-
ria were included [28,29]. IBD-U patients were grouped with
CD for the final analysis. Patients whose hospital medical
records were unavailable for review or who were enrolled in
an interventional clinical trial of an investigational medicinal
product during the observation period or who did not
receive vedolizumab or were recruited outside the data
range for the study were excluded.
Data collection
Data was extracted and anonymised after extensive examin-
ation of medical records onto a pre-defined Microsoft Excel
spreadsheet. The source data was a combination of clinical
electronic and paper records: outpatient letters, prescriptions,
day-case visits, laboratory and radiological investigations,
endoscopy reports, emergency admissions, radiological and
surgical intervention notes. Patient demographics prior to
starting vedolizumab and clinical characteristics before and
during each clinical visit for the whole treatment duration
was recorded. Nottingham University Hospitals was the coor-
dinating site which collated the data and raised any data
queries with each participating hospital.
Outcome measures and definitions
Clinical disease activity was assessed at baseline, week 14, 30
and 52 using the Harvey-Bradshaw Index (HBI) and partial
Mayo Score (pMS) [30,31]. Sixty-five percent of the disease
activity scores were prospectively recorded and thirty-five
percent of scores were calculated retrospectively from pro-
spectively collected raw data from medical records. Raw data
used for calculating scores was only used if the medical
records matched the parameters and clinical evaluations
used for the HBI and pMS scores. The primary outcome of
this study was to investigate corticosteroid-free clinical remis-
sion defined as HBI 4 or pMS <2 with a combined stool
frequency and rectal bleeding sub score of 1 and cortico-
steroid-free status after initiation of vedolizumab defined as
absence of corticosteroid concomitant administration within
two weeks either side of clinical scoring date. Secondary out-
comes included: time to first clinical remission and clinical
response (2-point decrease from baseline in pMS and 3-
point decrease from baseline in HBI), endoscopic remission
(absence of ulcers and inflammatory lesions assessed by
endoscopy or small bowel magnetic resonance enterogra-
phy) status at week 14 (±2weeks), week 30 (±2weeks) and
52 (±2weeks) weeks. Other outcome measures included
effect on disease activity scores, biochemical markers, con-
comitant drug use, hospital admissions (admission >24 h)
and adverse effects. Patients who failed to show an improve-
ment of symptoms and clinical signs with induction therapy
were termed ‘primary non-responders’. Loss of response was
defined as when patients lose response to vedolizumab ther-
apy over time.
Statistical analysis
Parametric variables are presented as mean with standard
deviations (SD) and non-parametric continuous variables as
medians with interquartile ranges [IQR]. Categorical variables
are described as frequency with percentages. Time-depend-
ent variables are presented as Kaplan–Meier plots. Wilcoxon
signed-rank test was used for analysis of continuous data. A
p-value of <.05 was considered as statistically significant.




A total of 206 patients were screened for the study. Fourteen
patients were excluded due to not receiving a scheduled first
dose of vedolizumab or the initiation date occurred outside
the date range for this study. Medical records were available
on all patients and none were enrolled into an interventional
clinical trial. One hundred ninety-two patients (CD: 99, IBD-U:
6, UC: 87) were treated with vedolizumab. Patient demo-
graphics and disease extent are summarised in Table 1. One
third of patients (29%) had a history of perianal involvement
at baseline. Approximately 57% of patients with CD had at
least one previous IBD related surgical procedure; 53% of
patients had been hospitalised 12 months prior to starting
vedolizumab, with a mean rate of hospitalisations during this
time of 1.1 (IQR: 0.0–1.0).
Most patients had prior treatment with corticosteroids
(96% and 98% for CD and UC, respectively) and immunomo-
dulators (94% and 93% for CD and UC, respectively). About
90% of CD and 54% of UC patients had previous biologic
therapy exposure; 45% and 46% of CD patients failed one or
two anti-TNF agents, respectively. For UC, exposure was 41%
and 13%, respectively for one or two anti-TNF agents.
Median exposure to vedolizumab was 31.0 [IQR 21.3–51.1]
weeks for CD and 38.4 [IQR 23.7–61.1] for UC (Table 2). The
median study observation period for CD and UC was
36.3weeks [IQR: 22.0–48.1, 10weeks n¼ 103; 26weeks
n¼ 72; 48weeks n¼ 30] and 40.4weeks [IQR:
23.0–56.6 10weeks n¼ 85; 26weeks n¼ 61; 48weeks
n¼ 34], respectively. Eleven patients with CD had vedolizu-
mab infusions at week 10 (9 and <11). Four of these
patients had only received two infusions of vedolizumab
prior to their week 10 infusion.
Clinical remission and response
Following initiation on vedolizumab in CD, 27/60 (45%) of
patients achieved corticosteroid-free remission with a median
time of 14.1weeks [IQR: 6.0–21.7]. For patients with UC, 39/
87(46%) achieved corticosteroid-free remission with median
time of 17.6weeks [IQR: 8.7–29.6], Figure 2. Clinical remission
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in CD was observed in 37/70 (44%) of patients (Table 3),
with a median time of 10.1weeks [IQR: 3.1–21.0]. For patients
with UC, clinical remission was observed in 25/48 (52%) of
patients with a median time of 15.1weeks [IQR: 7.4–24.9].
For patients with CD, 53% achieved clinical response with a
median time of 9.5weeks [IQR: 6.1–18.2]. For patients with
UC, 49% achieved clinical response with a median time of
9.4weeks [IQR: 5.7–15.4]. Figures 3 and 4 summarise clinical
remission for all IBD patients and according to prior anti-TNF
exposure for UC patients.
Disease activity
Clinical disease activity scores for UC reduced from baseline
to: 14weeks pMS 5 (IQR: 3–6) vs. 3 (IQR: 1–5) p¼ .025;
30weeks pMS 5 (IQR: 3–6) vs. 2(IQR: 1–5.5) p¼ .032; 52weeks
5 [IQR: 3–6] vs. pMS 2 [IQR: 0–5] p¼ .27. For CD, disease
activity scores decreased from baseline to: 14weeks HBI 7
(IQR: 5–11) vs. 5 (IQR: 3–7.5) p¼ .059; 30weeks HBI 7 (IQR:
5–11) vs. 6.5 (IQR: 2.5–8) p¼ .61; 52weeks HBI 7 (IQR: 5–11)
vs. 7 (IQR: 7–7) p¼ .78. Endoscopic remission (endoscopic
examination or MRI) was achieved in 53% (25/47), 45% (15/
33) and 50% (8/16) at 14, 30 and 52weeks after initiation of
vedolizumab, respectively. Endoscopically measured remis-
sion rates (based on SES-CD or endoscopic Mayo [UC] score)
were 88% (21/24), 78% (14/18) and 50% (5/10) at week 14,
30 and 52weeks, respectively. C-reactive protein for UC
decreased from baseline by 52weeks: 29.1mg/L vs. 13.4mg/
L and decreased from baseline for CD at 52weeks: 17.7mg/L
vs. 3.8mg/L. Faecal calprotectin decreased by 14weeks for
UC: 1145 mg/g vs. 664 mg/g and CD 361 mg/g vs. 270 mg/g.
Continuation of vedolizumab
At the end of the observation period, 63% of CD and 70% of
UC patients remained on vedolizumab. A total of 65 patients
discontinued vedolizumab therapy. The most common rea-
sons for discontinuing vedolizumab in patients with CD/IBDU
were primary non-response (28/36 [78%]) and intolerance
(5/36 [14%]). The most common reasons in patients with UC
were primary non-response (20/24 [83%]) and loss of
response (3/24 [13%]).
Table 1. Patient demographics.
Overall CD/IBDU UC
Number 192 105 (55%) 87 (45%)
Age
Mean (SD) 44.6 (16.1) 45.0 (15.5) 44.1 (16.8)
Gender
Female 97 (51%) 63 (60%) 34 (39%)
Male 95 (49%) 42 (40%) 53 (61%)
Ethnicity
Caucasian 171 (89%) 94 (90%) 77 (89%)
Asian 15 (8%) 8 (7.5%) 7 (8%)
Black 1 (0.5%) 1 (1%) 0 (0%)
Other/unknown 5 (2.5%) 2 (2%) 3 (3%)
Smoking status
Current 26 (14%) 23 (22%) 3 (3%)
Never 112 (58%) 50 (48%) 62 (71%)
Ex-smoker 29 (15%) 18 (17%) 11 (13%)
Unknown 25 (13%) 14 (13%) 11 (13%)
Malignancy history
Yes 12 (6%) 8 (8%) 4 (5%)
BMI
Median (IQR) 25.7 (22.5 to 31.4) 25.6 (21.9 to 31.5) 26.1 (23.0–31.3)
Disease extent (Montreal classification)
CD
Age at onset
A1 (<17 years) 21 (11%) 13 (13%) 8 (9%)
A2 (17–40 years) 103 (56%) 58 (58%) 45 (53%)
A3 ( 40 years) 61 (33%) 29 (29%) 32 (38%)
Disease behaviour
B1 (non-stricturing, non-penetrating or inflammatory) 50 (48%)
B2 (stricturing) 30 (29%)
B3 (penetrating) 24 (23%)
Disease location
L1 (ileal) 18 (17%)
L2 (colonic) 28 (27%)
L3 (ileocolonic) 50 (48%)
L4 (isolated upper disease)/Upper GI 8 (8%)
Perianal 30 (29%)
UC
E1 (ulcerative proctitis) 3 (3%)
E2 (distal or left sided UC) 52 (59%)
E3 (extensive UC or pancolitis) 33 (38%)
Disease duration (years)
Median 12.3 5.4
IQR 4.9 to 18.0 3.2 to 12.8
Variables presented as number (percentage) or median (IQR).
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Table 2. Treatment history.
Overall (n¼ 192) CD/IBDU (n¼ 105) UC (n¼ 87)
Vedolizumab indicationa
Endoscopic or radiological evidence of active disease 39 (20%) 22 (21%) 17 (20%)
Corticosteroid dependency 21 (11%) 2 (2%) 19 (22%)
Intolerance to immunomodulators 21 (11%) 9 (9%) 12 (14%)
Intolerant to TNF inhibitors 23 (12%) 19 (18%) 4 (5%)
Primary non-responders to TNF inhibitors 67 (35%) 35 (33%) 32 (37%)
Loss of response to TNF 21 (11%) 18 (17%) 3 (3%)
Corticosteroids
Y 186 (97%) 101 (96%) 85 (98%)
N 6 (3%) 4 (4%) 2 (2%)
Immunomodulators
Y 180 (94%) 99 (94%) 81 (93%)
N 12 (6%) 6 (6%) 6 (7%)
One immunomodulator 97 (51%) 55 (52%) 42 (48%)
Two immunomodulators 59 (31%) 29 (28%) 30 (34%)
Three immunomodulators 23 (12%) 14 (13%) 9 (10%)
Four immunomodulators 1 (1%) 1 (1%) 0 (0%)
Azathioprine
Y 150 (79%) 80 (76%) 70 (81%)
N 41 (21%) 25 (24%) 16 (19%)
Ciclosporin
Y 19 (10%) 3 (3%) 16 (19%)
N 172 (90%) 102 (97%) 70 (81%)
Mercaptopurine
Y 81 (42%) 44 (42%) 37 (43%)
N 110 (58%) 61 (58%) 49 (57%)
Methotrexate
Y 38 (20%) 32 (30%) 6 (7%)
N 153 (80%) 73 (70%) 80 (93%)
Anti-TNF status
Naive 50 (26%) 10 (10%) 40 (46%)
Experienced 142 (74%) 95 (90%) 47 (54%)
One anti-TNF agent 83 (43%) 47 (45%) 36 (41%)
Two anti-TNF agents 59 (31%) 48 (46%) 11 (13%)
Median (weeks) exposure to vedolizumab
Median (IQR) 32.3 (22.0-54.0) 31.0 (21.3–51.1) 38.4 (23.7–61.1)
aSome patients had more than one indication for vedolizumab therapy.
Figure 2. Kaplan-Meier plot of time to corticosteroid-free remission.
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Concomitant medication
For patients with CD, the number of patients with concomi-
tant medication use decreased over the time of the study. At
week 0, 27%, 26% and 23% of patients were co-prescribed
corticosteroids, immunomodulators and aminosalicylates,
respectively. By week 52, these proportions had decreased to
10%, 7% and 17%. A similar pattern was seen in patients
with UC; at week 0, 48%, 41% and 67% of patients were tak-
ing corticosteroids, immunomodulators and aminosalicylates,
respectively and by week 52 this had decreased to 15%, 18%
and 41%. In patients who remained on concomitant therapy
there was a reduction in the median dose from baseline
to week 52. Budesonide median dose reduced from
9mg (IQR: 6.0–9.0) at baseline to 2.5mg (IQR: 2.0–3.0) at
52weeks. Prednisolone median dose reduced from 30mg
(IQR: 27.5–40.0) at baseline to 20mg (IQR: 10.0–25.0)
at 52weeks.
Table 3. Rates of remission and response to vedolizumab achieved during
observation period.
CD UC
Corticosteroid free remission 45% 46%
Clinical remission 44% 52%
Clinical response 53% 49%
Figure 3. Kaplan-Meier plot of time to first clinical remission.
Figure 4. Kaplan-Meier plot of time to corticosteroid-free remission according to exposure to anti-TNF therapy for UC cohort only.
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Hospital admissions and adverse events
Patients (53%) had at least one hospital admission in the
12months preceding vedolizumab commencement. This
reduced to 30% during the observation period. The mean
rate of IBD-related hospital admissions prior to vedolizumab
initiation per patient per year for CD and UC was 1.0 (IQR
0–1.0) and 0.9 (IQR 0–2.0), respectively. Following vedolizu-
mab initiation, median rate of hospitalisation for CD and UC
were 1.0 (IQR 0–1.0) and 1.0 (IQR 0–1.0), respectively.
Twenty-six patients had IBD related surgery (12 patients with
CD and 14 patients with UC) during the observation period
after initiation of vedolizumab. Four of these patients had
two surgical procedures. Overall, 12 adverse events were
recorded in patients receiving vedolizumab during the study
observation period. The most common was intolerance of
vedolizumab (n¼ 5) (Table 4). About 9% of patients were
admitted with infections, with respiratory tract infections
being the most common. Three patients were diagnosed
with a malignancy during the observation period. One
patient was diagnosed with basal cell carcinoma and treated
with surgery. They received 14 doses of vedolizumab which
was later stopped due to loss of response. Another patient
who received four doses of vedolizumab (which was later
stopped due to non-response) was diagnosed with acute
myeloid leukaemia and was started on chemotherapy. The
final patient underwent a prostatectomy for prostate cancer.
The vedolizumab was continued for more than 12months by
the end of the observation period.
Discussion
Following initiation on vedolizumab, clinical remission in
patients with CD in this study was observed in 44% of
patients with a median time of 10.1weeks [IQR: 3.1–21.0].
For patients with UC, clinical remission was observed in 52%
of patients with a median time of 15.1weeks [IQR: 7.4–24.9].
In CD, 45% of patients achieved corticosteroid-free remission
with a median time of 14.1weeks [IQR: 6.0–21.7]. For patients
with UC, 46% achieved corticosteroid-free remission with
median time of 17.6weeks [IQR: 8.7–29.6]. Despite positive
results from the GEMINI licencing trials [15,16], real-world
data is needed to describe the effectiveness of new thera-
peutic agents in routine clinical practice. The majority of
patients in clinical practice do not fit the tight descriptors
typical of pivotal licencing trials. Findings from this multi-
centre cohort of patients with IBD demonstrate clinical
effectiveness that is comparable to results from randomised
controlled trials (RCTs) [15,16] and other studies
[23,25,32–36]. Data from this study are generalizable to the
rest of the UK due to the inclusion of both small district
general hospitals and tertiary centres. Often real-world stud-
ies are hampered by incomplete datasets with drug persist-
ence often being the primary outcome to determine long-
term effectiveness. This study uses clinically measured dis-
ease scores as the tool of choice, making our findings more
reflective of patient response to therapy.
Patient characteristics in this cohort, in particular median
age and gender distribution are typical for IBD in the UK.
Patients with CD were predominately anti-TNF experienced
with a median disease duration of over 12 years. This reflects
UK guidance from the National Institute of Health and Care
Excellence (NICE) for vedolizumab which recommends use
after an anti-TNF agent or when one is contraindicated.
Whereas in UC, vedolizumab is recommended for use in bio-
logic naive patients when conventional therapy has failed
[37,38]. In line with this UK guidance, the rates of corticoster-
oid and immunomodulatory drug use prior to initiation of
vedolizumab were similar to previous real-world stud-
ies [32,33,39].
Drug persistence for vedolizumab was 70% and 63%
respectively for UC and CD at the end of the study period,
similar to previous studies. Ylisaukko-Oja et al., a Finnish
cohort of 247 patients reported persistence rates of 66% and
75% for UC and CD, respectively at 6months initiation [40].
Stallmach et al., a prospective study reported rates of 68%
and 55% for UC and CD, respectively at week 30 [41].
Corticosteroid free remission, clinical remission and clinical
responses were approximately 50% in this cohort. The
GEMINI study reported clinical remission rates of 39% and
42% at 12 months for CD and UC, respectively [15,16] and
the recent VARSITY study in UC patients reported clinical
remission rates of 31.3% for vedolizumab patients at 12
months [42]. Real-world studies have reported clinical remis-
sion rates varying between 21% and 76%, measured at vari-
ous time-points up to 54 weeks, for both CD and UC [43].
In this study, UC response rates were lower than those in
CD. This finding is unique and had not been observed in
previous real world and licencing trials. Forty-eight percent
of UC patients were on concomitant corticosteroid therapy
at the start of vedolizumab therapy as opposed to 27% in
CD. Moreover, baseline disease activity in UC could be con-
sidered higher with a median pMS of 5 and a faecal calpro-
tectin of 1145 mg/g as compared to a median HBI of 7 and a
faecal calprotectin of 361 mg/g. These variables might indi-
cate differential disease severity at baseline in these two dis-
eases hence possibly explaining the observed efficacy in CD
as compared to UC. Corticosteroid use in this study was con-
sistent with previous studies which report rates between
29% and 84% [19,33,34,44,45]. Inflammatory burden of dis-
ease measured by CRP and FCP reduced following treatment
initiation as expected.
The safety profile during follow-up was comparable to
previous studies with rates of infections ranging between
1.7% and 12.6% [24,46,47]. However, the sample size and
follow-up period were too small to detect significant
safety signals.
Over the observation period approximately half of
patients with available endoscopic images or small bowel
Table 4. Distribution of adverse events in patients receiving vedolizumab.
CD/IBDU (n¼ 105) UC (n¼ 87) Overall (n¼ 192)
Total number of AEs 9 3 12
Intolerance 3 (33%) 2 (67%) 5 (42%)
Allergic 1 (11%) 0 (0%) 1 (8%)
Other 5 (56%) 1 (33%) 6 (50%)
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magnetic resonance enterography demonstrated endoscopic
remission. These data suggest endoscopic remission with
vedolizumab in both CD and UC though the number of
patients undergoing these repeated objective investigations
are relatively small (29 in CD and 18 in UC). The GEMINI 1
study reported mucosal healing rates in UC of 51.6% at
52weeks [16]. Dulai et al., a real-world study reported muco-
sal healing cumulative rates in CD of 63% by 52weeks of
therapy [45]. Over time, a significant number of patients
were able to de-escalate corticosteroid and immunomodula-
tor use. Previous trials have demonstrated superiority of
combination therapy (biologics with an immunomodulatory
agent) over monotherapy [48,49]. Benefit with vedolizumab
has not been extensively researched, however, post hoc ana-
lysis from GEMINI trials did not suggest additional benefit
[50]. Allegretti et al., a multi-centre retrospective study of
136 patients conducted in the US described higher clinical
responses for CD but not UC patients with combination ther-
apy [51].
This was the first study to describe the reduction in con-
comitant medication with vedolizumab therapy in a large
cohort of patients. Previous studies have described frequency
but not the actual dosage change with vedolizumab. This
study also describes ‘time-to’ data in a real-world setting,
with results comparable to those reported in the GEMINI and
VARSITY studies [15,16,42].
A major limiting factor for this study is the retrospective
nature of the design with significant potential for missing
data and short follow-up periods for some individuals. The
variability of real-world clinical follow-up might have led to
selection bias for clinical outcomes. The median time to ana-
lysis was defined by time seen in the clinic after induction
therapy as reflects real-world practice. Although the majority
of disease activity scores were recorded prospectively, some
were derived retrospectively from medical records which
may limit the accuracy of this data, an example of this is
higher values of steroid-free remission seen than complete
remission (baseline data was not always available to calculate
complete response, whereas steroid-free remission is an
absolute value at a specific timepoint). Endoscopic evaluation
was also not uniformly available. When available it tended to
be performed on individuals with a greater severity of dis-
ease. Mucosal healing observations should, therefore, be
interpreted with caution as this was only assessed in a quar-
ter of the cohort. Comparison with previous studies cannot
accurately be made due to the differences in sample size,
study region, clinical practice, patients and study outcome
measures. Disease activity scores used to define remission
and response vary amongst studies making interpretation
and comparison with other cohorts problematic. In this
study, a combination of disease activity scores and persist-
ence data were used. Shelton et al. reported simple clinical
colitis activity index (SCCAI); Lenti et al. reported physician
global assessments and Kopylov et al. used a combination
[24,34,35]. Although our patient numbers are comparable to
real-world studies, the sample size is severely limited when
compared to RCTs. The majority of our patients had previous
exposure to anti-TNF. This may be due to the fact that this
study was undertaken shortly after NICE approval of vedoli-
zumab in the UK and hence a large number of TNF-refractory
patients were switched to vedolizumab. This might indicate
the relatively more refractory nature of this cohort when
compared to published trials. Another limitation is that the
interpretation of adverse event rates is challenging due to
the retrospective design leaving the study open to recall bias
in the collection of data alongside the lack of a control
group. Moreover, another potential limitation was the lack
of central reading for endoscopy reports or radio-
logical imaging.
In this real-world vedolizumab cohort study, efficacy data
for both UC and CD mirror previous RCTs and real-world
data. A significant proportion of patients remained on vedoli-
zumab by the end of the observation period. Our data dem-
onstrated improved disease control, corticosteroid sparing
and a decline in concomitant drug use with a comparable
safety profile to phase III randomised controlled trials. In a
cohort of complex and disease refractory IBD patients, vedo-
lizumab is effective in a UK real-world setting.
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